tipifarnib has been researched along with Adenocarcinoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, RH; Andreopoulou, E; Cristofanilli, M; Fehn, K; Fineberg, S; Han, HS; Hershman, DL; Pellegrino, CM; Raptis, G; Sparano, JA; Vahdat, LT; Valero, V; Vigoda, IS; Wright, JJ | 1 |
| Bouche, O; Bugat, R; De Porre, P; Eckhardt, SG; Maurel, J; Michiels, B; Smith, D; Steward, WP; van de Velde, H | 1 |
| Gradishar, WJ; Guo, M; Li, T; Perez, EA; Sledge, GW; Sparano, JA; Wang, M | 1 |
| Abbruzzese, JL; Alpaugh, RK; Beard, M; Cohen, SJ; Ho, L; Hudes, GR; Lewis, NL; McLaughlin, S; Meropol, NJ; Perez-Ruixo, JJ; Ranganathan, S; Rogatko, A; Thistle, AM; Verhaeghe, T; Wang, H; Weiner, LM; Wright, JJ | 1 |
| Choudary, A; Freeman, JW; Venkatasubbarao, K | 1 |
| Bonanno, E; Capriotti, G; Cornelissen, B; Dierckx, RA; Kersemans, V; Lahorte, C; Signore, A; Slegers, G; Van de Wiele, C | 1 |
| Abbruzzese, JL; Giguere, JK; Iqbal, S; Macdonald, JS; McCoy, S; Wade, JL; Whitehead, RP | 1 |
| Abbruzzese, A; Baldi, A; Bertieri, R; Budillon, A; Caraglia, M; D'Alessandro, AM; Leonetti, C; Marra, M; Meo, G; Santini, D; Tonini, G; Zupi, G | 1 |
5 trial(s) available for tipifarnib and Adenocarcinoma
| Article | Year |
|---|---|
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Farnesyl-Diphosphate Farnesyltransferase; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2013 |
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Double-Blind Method; Europe; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Pain Measurement; Pancreatic Neoplasms; Patient Satisfaction; Placebo Effect; Quinolones; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States | 2009 |
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Quinolones; Taxoids; Treatment Outcome | 2012 |
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Carrier Proteins; Disease Progression; Farnesyltranstransferase; Female; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinolones; Treatment Outcome | 2003 |
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Proto-Oncogene Mas; Quinolones; Survival Rate; Treatment Outcome | 2005 |
3 other study(ies) available for tipifarnib and Adenocarcinoma
| Article | Year |
|---|---|
Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.
Topics: Adenocarcinoma; Alkyl and Aryl Transferases; Cell Cycle Proteins; Cell Growth Processes; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Interleukin-6; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-myc; Quinolones; Serine; STAT3 Transcription Factor; Trans-Activators; Tyrosine; Up-Regulation | 2005 |
In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy.
Topics: Adenocarcinoma; Alkyl and Aryl Transferases; Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Farnesyltranstransferase; Humans; Iodine Radioisotopes; Male; Mice; Mice, Nude; Prognosis; Quinolones; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2005 |
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinolones; ras Proteins; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |